SCHEMBL4720372

SCHEMBL4720372

O=C1Nc2c(Cl)cccc2C12CCCCC2

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE7A Q13946 6/20 0.59
PDE7B Q9NP56 2/20 0.59
PGR P06401 6/20 0.49
AHR P35869 1/20 0.41
MAPT P10636 1/20 0.39
HTR1A P08908 1/20 0.39
HTR2A P28223 1/20 0.39
HTR7 P34969 1/20 0.39
HTR6 P50406 1/20 0.39
PDE5A O76074 1/20 0.39
PDE4A P27815 1/20 0.39
PDE1A P54750 1/20 0.39
PDE1B Q01064 1/20 0.39
PDE4B Q07343 1/20 0.39
PDE4C Q08493 1/20 0.39
PDE4D Q08499 1/20 0.39
PDE1C Q14123 1/20 0.39
NSD2 O96028 1/20 0.39
BCHE P06276 1/20 0.39
DAO P14920 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29860150 0.91 PDE7A (0.51) PDE7APDE7BPGRAHRMAPT
SCHEMBL31436482 0.85 PDE7A (0.47) PDE7APDE7BPGRAHRMAPT
SCHEMBL29860086 0.84 PDE7A (0.46) PDE7APDE7BPGRAHRMAPT
SCHEMBL4078896 0.80 PDE7A (0.59) PDE7APDE7BPGR
SCHEMBL4717341 0.78 PDE7A (0.56) PDE7APGR
SCHEMBL4719333 0.76 PDE7A (0.57) PDE7APDE7BPGRHTR1AHTR2A
SCHEMBL11642237 0.75 PDE7A (0.56) PDE7APDE7BPGRHTR7PDE5A
SCHEMBL4716029 0.75 PDE7A (0.53) PDE7APGR
SCHEMBL29622110 0.75 PDE7A (0.53) PDE7APGRDAO
SCHEMBL20282798 0.72 PDE7A (0.40) PDE7APDE7BPGRPDE5APDE4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1931631-A1 1- (1H- INDOL- 1-YL) -3- (METHYLAMINO) -1- PHENYLPROPAN-2-OL DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS OF THE MONOAMINE REUPTAKE FOR THE TREATMENT OF VASOMOTOR SYMPTOMS (VMS) Wyeth a Corporation of the State of Delaware (US) 2008-06-18 EP disclosed
WO-2007041023-A1 1- (1H- INDOL- 1-YL) -3- (METHYLAMINO) -1- PHENYLPROPAN-2-OL DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS OF THE MONOAMINE REUPTAKE FOR THE TREATMENT OF VASOMOTOR SYMPTOMS (VMS) WYETH (US) 2007-04-12 WO disclosed
US-20070072897-A1 Phenylaminopropanol derivatives and methods of their use WYETH (US) 2007-03-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070072897-A1 Phenylaminopropanol derivatives and methods of their use COMT, PNMT, GLS PDE7A 258/4885PDE7B 285/4885PGR 230/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.